AU2008265595B2 - Substituted N-Aryl pyridinones as fibrotic inhibitors - Google Patents

Substituted N-Aryl pyridinones as fibrotic inhibitors Download PDF

Info

Publication number
AU2008265595B2
AU2008265595B2 AU2008265595A AU2008265595A AU2008265595B2 AU 2008265595 B2 AU2008265595 B2 AU 2008265595B2 AU 2008265595 A AU2008265595 A AU 2008265595A AU 2008265595 A AU2008265595 A AU 2008265595A AU 2008265595 B2 AU2008265595 B2 AU 2008265595B2
Authority
AU
Australia
Prior art keywords
compound
inhibitors
recited
acid
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008265595A
Other languages
English (en)
Other versions
AU2008265595A1 (en
Inventor
Thomas G. Gant
Sepehr Sarshar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puretech LYT 100 Inc
Original Assignee
Puretech LYT 100 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech LYT 100 Inc filed Critical Puretech LYT 100 Inc
Publication of AU2008265595A1 publication Critical patent/AU2008265595A1/en
Application granted granted Critical
Publication of AU2008265595B2 publication Critical patent/AU2008265595B2/en
Priority to AU2015200975A priority Critical patent/AU2015200975B2/en
Priority to AU2015261706A priority patent/AU2015261706B2/en
Assigned to PureTech LYT-100 Inc. reassignment PureTech LYT-100 Inc. Request for Assignment Assignors: AUSPEX PHARMACEUTICALS, INC.
Assigned to PureTech LYT 100 Inc. reassignment PureTech LYT 100 Inc. Request to Amend Deed and Register Assignors: PureTech LYT-100 Inc.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008265595A 2007-06-20 2008-06-20 Substituted N-Aryl pyridinones as fibrotic inhibitors Active AU2008265595B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2015200975A AU2015200975B2 (en) 2007-06-20 2015-02-26 Substituted n-aryl pyridinones
AU2015261706A AU2015261706B2 (en) 2007-06-20 2015-11-30 Substituted n-aryl pyridinones

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94513607P 2007-06-20 2007-06-20
US60/945,136 2007-06-20
PCT/US2008/067732 WO2008157786A1 (en) 2007-06-20 2008-06-20 Substituted n-aryl pyridinones as fibrotic inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015200975A Division AU2015200975B2 (en) 2007-06-20 2015-02-26 Substituted n-aryl pyridinones

Publications (2)

Publication Number Publication Date
AU2008265595A1 AU2008265595A1 (en) 2008-12-24
AU2008265595B2 true AU2008265595B2 (en) 2014-12-04

Family

ID=39731521

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008265595A Active AU2008265595B2 (en) 2007-06-20 2008-06-20 Substituted N-Aryl pyridinones as fibrotic inhibitors

Country Status (13)

Country Link
US (6) US8383823B2 (enExample)
EP (1) EP2170828B1 (enExample)
JP (1) JP5587184B2 (enExample)
KR (2) KR101583737B1 (enExample)
CN (2) CN101842355A (enExample)
AU (1) AU2008265595B2 (enExample)
CA (1) CA2691379C (enExample)
DK (1) DK2170828T3 (enExample)
ES (1) ES2400026T3 (enExample)
HK (1) HK1214251A1 (enExample)
IL (1) IL202840A (enExample)
NZ (1) NZ599643A (enExample)
WO (1) WO2008157786A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20110313004A1 (en) * 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
TWI434833B (zh) * 2009-06-03 2014-04-21 Intermune Inc 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
CN101921225B (zh) * 2009-06-11 2013-04-03 北京凯得尔森生物技术有限公司 吡啡尼酮类化合物、其制备方法和应用
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
HUE058753T2 (hu) * 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
BR112013022766A2 (pt) * 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
AU2012258575B2 (en) * 2011-05-25 2017-03-02 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
BR112014012288A2 (pt) 2011-11-22 2017-05-23 Intermune Inc métodos para diagnosticar e tratar fibrose pulmonar idiopática
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2882426A1 (en) * 2012-08-13 2015-06-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for treatment of cystic fibrosis
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
CN112057457A (zh) * 2013-03-13 2020-12-11 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20160331734A1 (en) * 2014-01-24 2016-11-17 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
MX2016010213A (es) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
US20150284327A1 (en) * 2014-04-04 2015-10-08 Auspex Pharmaceuticals, Inc. Oxindole inhibitors of tyrosine kinase
WO2015171345A1 (en) * 2014-04-30 2015-11-12 Auspex Pharmaceuticals, Inc. N-aryl pyridinones modulators of fibrosis and/or collagen infiltration
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
SG10202010157VA (en) * 2015-02-10 2020-11-27 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
EP3868374A3 (en) * 2016-03-22 2021-11-10 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
US10945999B2 (en) 2016-04-08 2021-03-16 Quretech Bio Ab Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
DK3529257T3 (da) 2016-10-18 2023-08-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
CN106748984A (zh) * 2016-11-22 2017-05-31 斯芬克司药物研发（天津）股份有限公司 6‑羟甲基‑1‑苯基吡啶‑2‑酮及其制备方法与应用
CA3108048A1 (en) * 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
CN108285431B (zh) * 2018-03-23 2021-04-09 北京康蒂尼药业股份有限公司 一种吡非尼酮有关物质及其制备方法和用途
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
IL319182A (en) * 2018-09-14 2025-04-01 Puretech Lyt 100 Inc Deuterium-enriched pirfenidone and methods of using it
WO2022010925A1 (en) * 2020-07-06 2022-01-13 Puretech Lyt 100, Inc. Methods of treating diseases and disorders with deupirfenidone
US20250114341A1 (en) 2018-09-14 2025-04-10 Puretech Lyt 100, Inc. Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
US20230129866A1 (en) 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
EP4121049A4 (en) * 2020-03-18 2024-04-03 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
AU2023205787A1 (en) * 2022-01-05 2024-06-13 Puretech Lyt 100, Inc. Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
CN114957106B (zh) * 2022-05-23 2024-01-30 湖北工程学院 药物吡非尼酮的流动相自动合成方法
WO2026133157A1 (en) 2024-12-16 2026-06-25 Puretech Lyt 100, Inc. Deupirfenidone for use for treating idiopathic pulmonary fibrosis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US20030194748A1 (en) * 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
US20060270618A1 (en) * 2001-12-18 2006-11-30 Dorian Bevec Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
WO2004019863A2 (en) 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2005013917A2 (en) 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
WO2005038056A1 (en) 2003-10-14 2005-04-28 Intermune, Inc. Combination therapy for the treatment of viral diseases
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
JP4072623B2 (ja) 2004-03-09 2008-04-09 独立行政法人産業技術総合研究所 ピリジン−ｎ−オキシド類の製造方法
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
AP2007004244A0 (en) * 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
EP2389227A4 (en) 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
CN102149682B (zh) 2009-05-25 2012-12-05 中南大学 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途
BR112013022766A2 (pt) 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
AU2012258575B2 (en) 2011-05-25 2017-03-02 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
US20160331734A1 (en) 2014-01-24 2016-11-17 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
WO2015171345A1 (en) 2014-04-30 2015-11-12 Auspex Pharmaceuticals, Inc. N-aryl pyridinones modulators of fibrosis and/or collagen infiltration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, B.-S. et al. Journal of Clinical Endocrinology and Metabolism (1998), 83(1), 219-223 *

Also Published As

Publication number Publication date
KR101583737B1 (ko) 2016-01-11
JP5587184B2 (ja) 2014-09-10
EP2170828B1 (en) 2012-11-21
NZ599643A (en) 2013-11-29
IL202840A (en) 2014-07-31
EP2170828A1 (en) 2010-04-07
CN104892498A (zh) 2015-09-09
KR101767849B1 (ko) 2017-08-11
ES2400026T3 (es) 2013-04-05
US20140348928A1 (en) 2014-11-27
US20140235677A1 (en) 2014-08-21
CA2691379A1 (en) 2008-12-24
US8969575B2 (en) 2015-03-03
IL202840A0 (en) 2010-06-30
US20140107040A1 (en) 2014-04-17
US9504677B2 (en) 2016-11-29
US9062001B2 (en) 2015-06-23
US20150250777A1 (en) 2015-09-10
AU2008265595A1 (en) 2008-12-24
KR20100050466A (ko) 2010-05-13
WO2008157786A1 (en) 2008-12-24
US8383823B2 (en) 2013-02-26
US8969576B2 (en) 2015-03-03
US8680123B1 (en) 2014-03-25
CA2691379C (en) 2015-06-09
US20080319026A1 (en) 2008-12-25
HK1214251A1 (zh) 2016-07-22
DK2170828T3 (da) 2013-03-04
CN101842355A (zh) 2010-09-22
KR20160007684A (ko) 2016-01-20
JP2010530897A (ja) 2010-09-16

Similar Documents

Publication Publication Date Title
CA2691379C (en) Substituted n-aryl pyridinones
US7638651B2 (en) Substituted cyclohexanones
US20090022706A1 (en) Substituted cyclohexenes
US20100234388A1 (en) Substituted pde5 inhibitors
US20080045588A1 (en) Preparation and utility of substituted amphetamines
US20080132555A1 (en) Preparation and utility of substituted phenyltetrazoles
US20080146573A1 (en) Preparation and utility of substituted oxzolidinones
CA2936245A1 (en) Substituted n-aryl pyridinones
US20080167312A1 (en) Preparation and utility of substituted allylamines
US20090005431A1 (en) Substituted pyrrolidines
AU2015261706B2 (en) Substituted n-aryl pyridinones
AU2015200975B2 (en) Substituted n-aryl pyridinones

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
TH Corrigenda

Free format text: IN VOL 25, NO 50, PAGE(S) 6310 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTS CEASED OR EXPIRED - 2008 DELETE ALL REFERENCE TO 2008265595.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PURETECH LYT-100 INC.

Free format text: FORMER OWNER(S): AUSPEX PHARMACEUTICALS, INC.

HB Alteration of name in register

Owner name: PURETECH LYT 100 INC.

Free format text: FORMER NAME(S): PURETECH LYT-100 INC.